Labat-Robert J, Gruber E, Bihari-Varga M
Connective Tissue Laboratory, UA CNRS 1174, Paris XII University School of Medicine, France.
Int J Biol Macromol. 1990 Feb;12(1):50-4. doi: 10.1016/0141-8130(90)90081-k.
The effect of purified human plasma fibronectin on LDL-GAG and LDL-PG complex formation was studied. Fibronectin added to LDL or to GAG or even to preformed LDL-GAG-Ca2+ complexes could inhibit complex formation and dissociated preformed complexes. Similar results were obtained with total serum instead of purified LDL: 1.2 mg fibronectin added to 1.0 mg LDL-cholesterol completely inhibited insoluble complex formation in the presence of Ca2+ between LDL and GAGs or LDL and PGs purified from aorta, whatever the order of mixing of the macromolecules. When fibronectin was added to preformed PG-LDL complexes however dissociation was less complete than with preformed LDL-GAG complexes (60% dissociation instead of 100% at similar concentration ratios). It appears therefore that the protein and GAG portions of PGs may not interact at the same sites of LDL and competition by fibronectin would be more efficient at the GAG binding site. Fibronectin could also dissociate LDL-heparin complexes formed on heparin-Sepharose affinity columns. As PG-LDL complexes were isolated from atherosclerotic plaques and fibronectin was also shown to increase in plaque area and exhibit opsonic-like functions, the above findings may well have physiopathological significance.
研究了纯化的人血浆纤连蛋白对低密度脂蛋白-糖胺聚糖(LDL-GAG)和低密度脂蛋白-蛋白聚糖(LDL-PG)复合物形成的影响。将纤连蛋白添加到低密度脂蛋白、糖胺聚糖甚至预先形成的LDL-GAG-Ca2+复合物中,均可抑制复合物的形成并使预先形成的复合物解离。用全血清代替纯化的低密度脂蛋白也得到了类似的结果:在存在Ca2+的情况下,将1.2毫克纤连蛋白添加到1.0毫克低密度脂蛋白胆固醇中,可完全抑制从主动脉纯化的低密度脂蛋白与糖胺聚糖或低密度脂蛋白与蛋白聚糖之间不溶性复合物的形成,无论大分子混合的顺序如何。然而,当将纤连蛋白添加到预先形成的PG-LDL复合物中时,解离不如预先形成的LDL-GAG复合物完全(解离率为60%,而在相似浓度比下为100%)。因此,似乎蛋白聚糖的蛋白质和糖胺聚糖部分可能不在低密度脂蛋白的相同位点相互作用,纤连蛋白在糖胺聚糖结合位点的竞争可能更有效。纤连蛋白还可使在肝素-琼脂糖亲和柱上形成的LDL-肝素复合物解离。由于PG-LDL复合物是从动脉粥样硬化斑块中分离出来的,并且纤连蛋白也被证明在斑块面积中增加并表现出类似调理素的功能,上述发现很可能具有生理病理学意义。